

The correspondence section is a public forum and, as such, is not peer-reviewed. EHP is not responsible for the accuracy, currency, or reliability of personal opinion expressed herein; it is the sole responsibility of the authors. EHP neither endorses nor disputes their published commentary.

Cycling: Health Benefits and Risks

doi:10.1289/ehp.1003227

de Hartog et al. (2010) quantified the balance between physical activity and air pollution and accident risks of cycling and concluded that the benefits outweigh the risks by an order of magnitude. This is the most comprehensive and quantitative comparison to date, based on the published data available at the time. In the weeks after publication of the article, two new relevant studies were published; this illustrates that a scientific answer to this question is urgent from the societal perspective. In many places cyclists are perceived to have a higher exposure to air pollution and a higher accident risk. Do the new data tilt the balance between the risks and benefits of cycling?

de Hartog et al. (2010) used a ventilation rate that is twice as high for cyclists as for car drivers. In a recent study in Belgium (Int Panis et al. 2010), we found that both the ventilation rate and the tidal volume were increased and that minute ventilation was 4.3 times higher in cyclists compared with car passengers (similar to the ratio of metabolic rates). The difference can further be explained by differences in cycling speeds and lung deposition resulting in a dose that is up to 9 times higher in cyclists.

The life expectancy (LE) loss estimated from substituting this ratio into the calculation by de Hartog et al. (2010) may thus offset most of the expected LE gain. However, this is unlikely because some studies have observed an LE gain in the presence of air pollution (Andersen et al. 2000). To resolve this conflict, it is important to consider the implicit assumptions in the comparison.

First, the higher dose ratios apply only to situations without route choice, although cyclists prefer to avoid motorized traffic, which exposes them to lower concentrations (Zuurbier et al. 2009). Second, an LE loss calculation based on long-term studies assumes a linear relationship between the risk and the daily dose. Exposure to short, high bursts of traffic exhaust may be different from an exposure to the same dose over a longer period. Assuming a linear exposure response function leads to overestimation of the impact of peak exposures. Third, cyclists are not a random sample from the general population. Air pollution mortality is often associated with the elderly and individuals with cardiovascular problems, but most cyclists are neither old nor very likely to suffer from bad health. Also, LE loss calculations cannot distinguish between situations in which a few people suffer a high

LE loss or those in which many people have a small loss (Rabl 2003). Cyclists are generally young and in excellent health and therefore less vulnerable, implying that the relative risk used by de Hartog et al. (2010) is too high for application to this specific population.

In addition, accidents remain an important cause for concern. Aertsens et al. (2010) recently estimated the cost of minor bicycle accidents at an astonishing 0.12€/km cycled. Including the more serious accidents in the equation would yield a cost that could easily offset the value of the LE benefit calculated by de Hartog et al. (2010).

If the higher LE observed in present day cyclists can be transferred to people now taking up cycling, the benefits will probably be higher than the risks. However, it will be crucial to demonstrate that cycling increases physical activity. Without increased physical activity there are only risks, but reducing those risks may yield larger benefits than anticipated.

The views and opinions expressed in this article are those of the author and not necessarily those of his employer.

L.I.P. received financial support from the Science for Sustainable Development programme (2007–2010) of the Belgian Science Policy Office and strategic research funding from VITO (Flemish Institute for Technological Research) for the SHAPES (Systematic Analysis of Health Risks and Physical Activity Associated with Cycling Policies) project but has no competing financial interests. VITO is a public research institute of the Flemish regional government.

Luc Int Panis

VITO (Flemish Institute for Technological Research)
Mol, Belgium
E-mail: luc.intpanis@vito.be

REFERENCES

- Aertsens J, de Geus B, Vandenbulcke G, Degraeuwe B, Broekx S, De Nocker L, et al. 2010. Commuting by bike in Belgium, the costs of minor accidents. *Accid Anal Prev* 42:2149–2157.
- Andersen L, Schnohr P, Schroll M, Hein H. 2000. All-cause mortality associated with physical activity during leisure time, work, sports, and cycling to work. *Arch Intern Med* 160:1621–1628.
- de Hartog JJ, Boogaard H, Nijland H, Hoek G. 2010. Do the health benefits of cycling outweigh the risks? *Environ Health Perspect* 118:1109–1116.
- Int Panis L, de Geus B, Vandenbulcke G, Willems H, Degraeuwe B, Bleux N, et al. 2010. Exposure to particulate matter in traffic: a comparison of cyclists and car passengers. *Atmos Environ* 44(19):2263–2270.
- Rabl A. 2003. Interpretation of air pollution mortality: number of deaths or years of life lost? *J Air Waste Manag Assoc* 53(1):41–50.
- Zuurbier M, Hoek G, van den Hazel P, Brunekreef B. 2009. Minute ventilation of cyclists, car and bus passengers: an experimental study. *Environmental Health* 8:48; doi:10.1186/1476-069X-8-48 [Online 27 October 2009].

Cycling: de Hartog et al. Respond

doi:10.1289/ehp.1003227R

We thank Int Panis for his thoughtful comments on our article (de Hartog et al. 2010), and we broadly agree with his comments. In fact, we discussed most of the issues—including the limitation to impact on mortality, sensitive subgroups, route choice, and activity substitution—in our paper.

The first issue discussed by Int Panis is whether we underestimated the difference in minute ventilation between cyclists and car drivers; however, his comment was based on a recent Belgian study (Int Panis et al. 2010) that was not published at the time of our study. In our analysis we used a ratio of 2.2 [the average of two Dutch studies that closely agreed (van Wijnen et al. 1995; Zuurbier et al. 2009)], whereas the Belgian study (Int Panis et al. 2010) found a ratio of 4.3. The difference is probably explained in part by differences in cycling speed: 12 km/hr in the recent Dutch study (Zuurbier et al. 2009) and > 19 km/hr in the Belgian study (Int Panis et al. 2010). In urban areas, the average cycling speed is about 15 km/hr, including stop time. Rather than replacing the previous estimates by with the newer Belgian estimate, we believe that the best current estimate would be the average of the ratios of the three available studies. This would lead to a ratio of 2.9. Use of this ratio based on more studies clearly would not tip the balance between cycling and car driving as Int Panis suggests. We think it is stretching the data too much to use deposited particle mass (actually 5.9–8.99 higher in the Belgian study) for the analysis, because the long-term epidemiological studies we used are based on concentrations measured in outdoor air. In the most likely estimate we provided for air pollution [based on black smoke, which better represents traffic exposures than PM_{2.5} (particulate matter < 2.5 μm in aerodynamic diameter)], even including these estimates would not make a difference.

As we noted in the “Discussion” of our article (de Hartog et al. 2010), cyclists have more opportunity in urban areas to choose low-exposure routes. This would indeed result in smaller differences in inhaled doses between cyclists and car drivers than we used. We agree that we may have overestimated the air pollution risks related to cycling because, in general, subjects who cycle are healthier than those who respond in long-term epidemiological studies. However, with increasing evidence that air pollution—through oxidative stress and inflammation—may also increase preclinical cardiovascular disease, including